Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Documenti analoghi

• The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
  di: van den Bemt, Bart J F, et al.
  Pubblicazione: (2013)
• Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
  di: van den Bemt, Bart JF, et al.
  Pubblicazione: (2011)
• Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
  di: den Broeder, Alfons A, et al.
  Pubblicazione: (2013)
• DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
  di: van Riel, Piet LCM, et al.
  Pubblicazione: (2005)
• Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
  di: Verhoef, Lise M, et al.
  Pubblicazione: (2019)